Evidence map›Paper›PMID 37568105›Full record

ArticleBMC gastroenterology2023

Protective role of thymoquinone in hyperlipidemia-induced liver injury in LDL-R

Fei Wang, Wei Yao, Dexin Yu, Yuhua Hao, Yuling Wu, Xiaoqing Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Effects of fermentedFrontiers in pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Fei Wang *Department of Gastroenterology, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China.
Wei Yao *Department of Internal Medicine, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China.
Dexin YuDepartment of Internal Medicine, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China.
Yuhua HaoDepartment of Injection, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China.
Yuling WuDepartment of Injection, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China.
Xiaoqing ZhangDepartment of Injection, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China. dalian0199@sina.com.
Affiliated Zhongshan Hospital of Dalian University · CN

Funding

China's Dalian Medical Science Research Program 1911107
6 · The paper itself

Abstract

backgroundHyperlipidemia, a heterogeneous group of disorders characterized by elevated plasma lipids in the blood, causes severe health problems, leading to fatty liver disease and nonalcoholic fatty liver disease. Thymoquinone, the major active chemical component of Nigella sativa, reportedly exerts a vast array of biological effects. Various studies have reported that Thymoquinone protects against liver injury.

aimsThe aim of this study was to investigate the possible protective effects of Thymoquinone against liver injury in hyperlipidemia-induced LDL-R

methodsEight-week-old male LDL-R

resultsOur results demonstrated that Thymoquinone administration significantly reduced liver histological alterations by hyperlipidemia. Thymoquinone mitigated hyperlipidemia-induced liver injury as indicated by the suppression of metabolic characteristics, liver biochemical parameters, pyroptosis indicators, a macrophage marker, and the phosphatidylinositide 3-kinase signaling pathway.

conclusionsThymoquinone is a potential therapeutic agent for hyperlipidemia-induced liver injury.

Indexed as

Chemical and Drug Induced Liver Injury, ChronicHyperlipidemiasNon-alcoholic Fatty Liver DiseaseAnimalsBenzoquinonesCholesterolLiverMaleMiceBenzoquinonesCholesterolthymoquinoneHyperlipidemiaLDL-R−/− miceLiver injuryPyroptosisThymoquinoneWestern blotting

Identifiers

PMID37568105
PMCPMC10416449
OpenAlexW4385763613

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.